Nutrigenomics Market (2025 - 2035)

Nutrigenomics Market Research Report By Application (Personalized Nutrition, Disease Prevention, Health Optimization, Fitness and Athletic Performance), By End Use (Healthcare, Dietary Supplements, Food Beverage, Pharmaceuticals), By Product Type (Genetic Testing Kits, Bioinformatics Tools, Nutritional Analysis Software), By Technology (DNA Sequencing, Microarray Analysis, Polymerase Chain Reaction) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
ID: MRFR/Pharma/2692-CR
94 Pages
Satyendra Maurya, Rahul Gotadki
Last Updated: June 30, 2026
Nutrigenomics Market
Market Size
Forecast Period2025-2035
CAGR (2025-2035)16.4%
2025 Market SizeUSD 0.86 Billion
2035 Market SizeUSD 3.89 Billion
Key Players
Nutrigenomix Inc.
Prenetics
23andMe
Viome Life Sciences
Metagenics
DSM-Firmenich
Trends
  • Collapsing Sequencing Costs
  • Preventive Healthcare Policy Mandates
  • AI-Powered Nutrition Algorithms
Opportunities
  • Employer-Sponsored Precision Wellness Programs
  • Subscription-Based Personalized Supplement Delivery
  • Emerging-Market Mobile Health Platforms
Request Free Sample

Nutrigenomics Market Summary

The Global Nutrigenomics Market size was valued at USD 0.86 Billion in 2025, and the market is projected to grow from USD 0.99 Billion in 2026 to USD 3.89 Billion by 2035, registering a CAGR of 16.4% during the forecast period 2026–2035. Two forces are pulling this growth forward: falling genome-sequencing costs — which dropped from roughly USD 100 million in 2001 to under USD 650 today [1] — and a global policy pivot toward preventive healthcare that prioritizes early dietary intervention over reactive treatment [2]. Insurers and large employers now fund nutrigenomic screening as part of corporate wellness packages, driving sustained commercial adoption.

The Nutrigenomics Market is undergoing a fundamental technology shift. Legacy one-size-fits-all supplementation regimes are giving way to algorithm-driven platforms that cross-reference single-nucleotide polymorphisms with metabolomic data to generate individualized nutrition protocols [3]. The NIH's All of Us precision-medicine initiative, backed by more than USD 1.4 billion in cumulative funding, has accelerated clinical-grade validation of gene-diet interaction models [4]. Microbiome sequencing layered onto genomic profiling represents the next analytical frontier, blending gut-health data with DNA to refine macronutrient and supplement recommendations.

North America commands the largest share of the Nutrigenomics Market, contributing roughly 42.0% of global revenue in 2025, anchored by high consumer willingness to pay for direct-to-consumer genetic kits. Asia-Pacific is the fastest-growing region at a 14.5% CAGR, fueled by mobile-first health platforms scaling rapidly across India, China, and Southeast Asia [5]. Europe holds the second-largest share at approximately 28.5%, supported by EU Horizon Europe research grants targeting precision nutrition [6]. As regulatory frameworks mature and sequencing costs continue to compress, the Nutrigenomics Market is positioned for sustained double-digit expansion through 2035.

 

Key Report Takeaways

• By Application

  • Obesity-related applications accounted for 37.9% of the Nutrigenomics Market share in 2025, reflecting the global chronic-disease burden driving demand for gene-guided weight-management programs.
  • Cancer-focused nutrigenomics applications are expanding at a 13.6% CAGR through 2035, as oncology researchers integrate dietary interventions with treatment regimens.
  • Cardiovascular disease applications represented approximately USD 0.18 billion in 2025, supported by growing clinical evidence linking gene variants to lipid metabolism responses.

• By Product

  • Vitamins and minerals led the Nutrigenomics Market with a 33.1% revenue share in 2025, driven by established consumer recognition and broad retail availability.
  • Probiotics and prebiotics products are advancing at a 13.2% CAGR, as microbiome science validates strain-specific supplementation based on individual genetic profiles.

• By Region

  • North America contributed 42.0% of the Nutrigenomics Market revenue in 2025, underpinned by a mature DTC testing ecosystem.
  • Asia-Pacific is scaling at a 14.5% CAGR, with mobile health platforms in India and China onboarding millions of first-time users annually.

 

Nutrigenomics Market Size and Forecast (2021–2035)

Market Research Future's proprietary estimation framework integrates bottom-up revenue modeling from company financials, end-user surveys across 28 countries, patent-filing trend analysis, and cross-validation against publicly reported sequencing-volume data. Historical figures (2021–2024) reflect actual market performance; 2025 is the calibrated base year; and 2026–2035 values are projected under a steady-state growth scenario incorporating expected regulatory catalysts.

Nutrigenomics Market Size and Forecast
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Driver Impact Analysis

Driver ~% Impact on CAGR Geographic Relevance Impact Timeline
Collapsing sequencing costs ~25% Global Short-term (≤2 yr)
Preventive healthcare policy mandates ~20% North America, Europe Medium-term (2–4 yr)
AI-powered nutrition algorithms ~18% Global Medium-term (2–4 yr)
Microbiome science integration ~15% North America, Asia-Pacific Long-term (≥4 yr)
Corporate wellness & insurer incentives ~10% North America, Europe Short-term (≤2 yr)
Mobile-first DTC platforms in emerging markets ~8% Asia-Pacific, South America Medium-term (2–4 yr)
Regulatory harmonization (EU MDR, FDA LDT) ~4% Europe, North America Long-term (≥4 yr)

 

Collapsing Sequencing Costs

Since the Human Genome Project era, the price of whole-genome sequencing has dropped by over 99.9%. An estimated price for a consumer-grade test is roughly USD 600 in 2025 [1]. This price compression changes nutrigenomics from a clinical specialty service to a mass-market consumer product. Illumina’s NovaSeq X series and Element Biosciences’ AVITI are driving per-genome costs down to around USD 100, and analysts expect this to unleash uptake among price-sensitive groups in South and Southeast Asia.

 

Preventive Healthcare Policy Mandates

Government healthcare budgets globally are pivoting toward prevention. The UK's NHS Long Term Plan allocates GBP 4.5 billion toward genomic medicine infrastructure through 2028 [2]. These policy frameworks create direct reimbursement pathways for the Nutrigenomics Market.

AI-Powered Nutrition Algorithms

Machine-learning platforms that integrate polygenic risk scores with dietary recall data can generate personalized meal plans in under 60 seconds. This accelerates adoption among healthcare providers operating within the Nutrigenomics Market.

Microbiome Science Integration

By overlaying 16S rRNA and shotgun metagenomic sequencing on top of existing DNA genotyping, we construct a dual-data personalization engine. The American Gut Project, with over 30,000 participant samples, has given the training datasets for commercial microbiome-nutrigenomic solutions [10]. Companies in the Nutrigenomics Market are progressively integrating gut-health profiling with genetic kits to generate greater average order values.

 

 

Restraints Impact Analysis

Restraint ~% Drag on CAGR Geographic Relevance Impact Timeline
Consumer data privacy concerns ~–3.5% Global Ongoing
Limited clinical validation for some claims ~–2.8% Global Medium-term
Regulatory fragmentation across jurisdictions ~–2.2% Europe, Asia-Pacific Long-term
High out-of-pocket cost in developing markets ~–1.5% South America, MEA Medium-term
Physician skepticism and low referral rates ~–1.0% Global Short-term

 

Consumer Data Privacy Concerns

Genetic data is among the most sensitive personal information a consumer can share. The absence of a unified global standard — GDPR applies in Europe, GINA covers employment discrimination in the U.S., and many Asian markets lack dedicated genetic-data legislation — creates consumer hesitation [13].

Limited Clinical Validation

There is strong evidence for some gene-diet interactions (e.g., MTHFR variations and folate metabolism), although many commercial nutrigenomic recommendations are derived from genome-wide association studies with small effect sizes [14]. The FDA has not developed a formal approval process for nutrigenomic dietary recommendations, leaving the Nutrigenomics Market open to challenges to its credibility by advocates of evidence-based medicine.

 

Regulatory Fragmentation

The European Union’s In Vitro Diagnostic Regulation (IVDR), which came into force in May 2022, has very different classification standards for genetic tests than the FDA’s Laboratory Developed Test framework [6]. Companies moving across regions have to confront overlapping compliance standards, resulting in increased market-entry costs and hence slowing down worldwide progress within the Nutrigenomics Market.

 

 

Nutrigenomics Market Opportunities

Employer-Sponsored Precision Wellness Programs

In the United States, large firms spend an average of USD 15,000 a year on healthcare per employee [9]. Nutrigenomic screening – less than USD 300 per employee — provides an attractive ROI in terms of identifying metabolic risk profiles early and customizing dietary interventions. Corporate contracts are a high-volume recurring-revenue channel for Nutrigenomics Market participants.

 

Subscription-Based Personalized Supplement Delivery

Pairing genetic insights with monthly subscription boxes of custom-formulated supplements creates a sticky business model with 70%+ gross margins. Companies that own both the testing platform and the fulfillment pipeline can capture lifetime customer value exceeding USD 2,000. This vertical integration opportunity is reshaping competitive dynamics in the Nutrigenomics Market.

Emerging-Market Mobile Health Platforms

India's Ayushman Bharat Digital Mission and China's Healthy China 2030 initiative are digitizing healthcare delivery at national scale [5]. Mobile-first nutrigenomics platforms that offer affordable saliva-based genotyping paired with vernacular-language dietary guidance can tap populations of over 2.8 billion across these two markets alone.

Pharmacogenomic-Nutrition Convergence

Integrating drug-gene interaction data with nutrient-gene models creates a unified precision-health platform. Patients on statins, for example, can receive simultaneous guidance on CoQ10 supplementation based on their SLCO1B1 genotype [12]. This convergence expands the addressable Nutrigenomics Market beyond wellness into clinical pharmacy.

Data Monetization Through Anonymized Cohort Insights

Aggregated, de-identified nutrigenomic datasets hold significant value for pharmaceutical R&D, food product development, and population-health research. Companies with large genotyped consumer bases can license anonymized insights as a secondary revenue stream, diversifying beyond test-kit sales.

 

Nutrigenomics Market Future Outlook

AI and Multi-Omic Integration

By 2030, standalone genotyping will give way to multi-omic platforms that simultaneously analyze genomic, proteomic, metabolomic, and microbiome data. The global AI-in-genomics segment is projected to exceed USD 6.5 billion by 2030 [11], and nutrigenomics companies that embed deep-learning engines into their recommendation workflows will capture disproportionate market share within the Nutrigenomics Market.

Platform Economics and Vertical Integration

The Nutrigenomics Market is shifting toward vertically integrated platforms that own the full stack — from saliva-collection kits to AI-driven dietary plans to subscription supplement fulfillment. Platform models reduce customer acquisition costs by 40–60% compared to standalone testing services, and recurring-revenue subscriptions stabilize cash flows against test-volume cyclicality.

Regulatory Maturation and Clinical Standardization

The FDA's evolving framework for Laboratory Developed Tests, finalized by 2024, imposes consistent accuracy and validity requirements on nutrigenomic assays sold in the U.S. [6]. The EU's European Health Data Space regulation, targeted for implementation by 2029, will standardize cross-border genetic data sharing, enabling pan-European Nutrigenomics Market scalability [6].

ESG, Population Health, and Preventive ROI

Public-health systems globally face unsustainable chronic-disease spending — the WHO estimates that the global macroeconomic losses from the four primary non-communicable diseases would hit USD 30 trillion by 2030, attributing the separate USD 17 trillion metric specifically to the global cumulative losses from mental health conditions. Gene-guided dietary intervention offers a scalable, evidence-based prevention tool. ESG-focused investors increasingly view the Nutrigenomics Market as aligned with UN Sustainable Development Goal 3 (Good Health and Well-Being), channeling capital toward companies demonstrating measurable health-outcome improvements.

 

Nutrigenomics Market Segmentation

By Application

Segment Key Metric Primary Demand Driver
Obesity 37.9% share (2025) Global obesity epidemic, gene-guided weight management
Cancer 13.6% CAGR (2026–2035) Oncology nutrition integration, epigenomic research
Cardiovascular Diseases USD 0.18 Billion (2025) Lipid metabolism gene variants, statin-nutrient interactions
Other Applications 11.8% CAGR (2026–2035) Diabetes, neurological conditions, sports nutrition

 

Obesity dominates the Nutrigenomics Market application landscape. With over 890 million adults classified as obese globally by the WHO in 2024 [23], demand for genetically tailored dietary interventions continues to outpace other categories. Companies such as Nutrigenomix and DNAfit have built their core commercial propositions around weight-management gene panels that map FTO, MC4R, and ADRB2 variants to macronutrient recommendations.

Cancer-related nutrigenomics is the fastest-expanding application within the Nutrigenomics Market. Emerging research links specific polymorphisms (e.g., MTHFR C677T) to folate metabolism pathways implicated in colorectal cancer risk, creating clinical demand for gene-informed dietary surveillance [14].

By Product

Segment Key Metric Primary Demand Driver
Vitamins & Minerals 33.1% share (2025) Established category, broad retail access
Probiotics & Prebiotics 13.2% CAGR (2026–2035) Microbiome science, gut-brain axis research
Diagnostic Kits & Reagents USD 0.22 Billion (2025) Clinical-grade genotyping demand

 

Vitamins and minerals remain the revenue backbone of the Nutrigenomics Market product mix, benefiting from consumer trust in established supplement categories and straightforward regulatory pathways. Probiotics and prebiotics represent the growth frontier, propelled by mounting evidence that strain-specific supplementation guided by individual microbiome composition delivers superior health outcomes compared to generic formulations [10].

By End User

Segment Key Metric Primary Demand Driver
Direct-to-Consumer 51.2% share (2025) At-home kit convenience, digital marketing reach
Hospitals & Clinics 14.9% CAGR (2026–2035) Clinical integration and physician adoption
Research Institutes USD 0.09 Billion (2025) Grant-funded genomics studies

 

The direct-to-consumer channel commands the majority of the Nutrigenomics Market, as consumers increasingly bypass traditional healthcare gatekeepers to access genetic insights directly. Online marketing, influencer partnerships, and streamlined kit-to-result workflows have reduced the DTC customer journey to under 21 days in leading markets.

By Distribution Channel

Segment Key Metric Primary Demand Driver
Online Platforms 56.0% share (2025) E-commerce growth, subscription models
Offline (Retail, Clinics) 10.8% CAGR (2026–2035) Pharmacy partnerships, in-clinic testing

 

Online distribution dominates the Nutrigenomics Market, with e-commerce platforms and brand-direct websites accounting for the majority of consumer test-kit sales. The channel's strength reflects the inherently digital nature of the product: consumers order kits online, mail saliva samples, and receive results via app or web portal.

 

Regional Market Share Analysis

Region Key Metric Primary Investment Themes
North America 42.0% share (2025) DTC genetic testing, insurer partnerships, clinical integration
Europe 28.5% share (2025) Horizon Europe precision nutrition grants, IVDR compliance
Asia-Pacific 14.5% CAGR (2026–2035) Mobile health platforms, middle-class wellness spending
South America USD 0.05 Billion (2025) Public-health genomics pilots, telemedicine expansion
Middle East & Africa 4.5% share (2025) Government health-vision programs, medical tourism
Total USD 0.86 Billion (2025) —

The Nutrigenomics Market exhibits a distinct geographic hierarchy, with North America dominating revenue contribution and Asia-Pacific leading growth velocity. Regional dynamics reflect differences in regulatory infrastructure, consumer genomics literacy, healthcare spending patterns, and digital health adoption.

 

North America

Country Key Metric Key Driver
US 74.5% of regional share Mature DTC ecosystem, ACA preventive mandates [2]
Canada 15.8% CAGR Provincial health innovation funds [16]
Mexico USD 0.02 Billion Growing middle-class wellness awareness [5]

 

The United States anchors the Nutrigenomics Market in North America, driven by widespread consumer familiarity with at-home genetic kits and a reimbursement environment that increasingly covers genetic counseling services. Canada's genomics strategy, backed by Genome Canada's CAD 280 million investment pipeline, is catalyzing academic-commercial partnerships that translate research into commercial products [16].

Europe

Country Key Metric Key Driver
Germany 23.2% of regional share Strong pharma-nutrition crossover R&D [6]
UK 14.8% CAGR NHS Genomic Medicine Service expansion [2]
France USD 0.04 Billion National nutrition and health program (PNNS) [17]
Italy 10.5% of regional share Mediterranean-diet genomics research tradition [14]
Spain 12.6% CAGR Biobanking infrastructure investment [18]
Nordic Countries USD 0.03 Billion High digital-health penetration
Russia 4.2% of regional share Emerging private-sector genomics labs
Rest of Europe 13.8% CAGR EU cross-border health data regulation [6]

 

Europe's Nutrigenomics Market benefits from the EU's commitment to precision medicine through Horizon Europe, which earmarks over EUR 8.2 billion for health cluster research during 2021–2027 [6]. The UK's NHS Genomic Medicine Service, currently sequencing 300,000 genomes annually, provides a clinical infrastructure that nutrigenomics companies can leverage for validation studies [2].

Asia-Pacific

Country Key Metric Key Driver
China 32.8% of regional share Healthy China 2030 policy, BGI ecosystem [5]
India 17.2% CAGR Ayushman Bharat digital health stack [5]
Japan USD 0.03 Billion Aging-population nutrition innovation [19]
South Korea 15.1% CAGR K-Bio strategy and genomics investment [20]
ASEAN 13.8% of regional share Mobile-first health platforms [5]
Rest of Asia-Pacific USD 0.01 Billion Early-stage market development

 

Asia-Pacific represents the fastest-growing frontier for the Nutrigenomics Market. China's BGI Genomics operates the world's largest sequencing capacity, enabling low-cost consumer genomics, while India's rapidly expanding digital health infrastructure connects rural populations to telehealth-based nutrition guidance [5].

South America

Country Key Metric Key Driver
Brazil 58.0% of regional share FAPESP genomics research grants [21]
Argentina 14.2% CAGR University-led precision nutrition pilots
Rest of South America USD 0.01 Billion Early adoption phase

 

Brazil dominates the South American Nutrigenomics Market, supported by the country's advanced biomedical research infrastructure and FAPESP-funded genomics programs [21]. Argentina's public university system is producing early clinical evidence linking regional dietary patterns to genetic predispositions.

Middle East & Africa

Country Key Metric Key Driver
Saudi Arabia 30.5% of regional share Vision 2030 health-sector investment [22]
UAE 16.0% CAGR Medical tourism and premium wellness clinics [22]
South Africa USD 0.005 Billion Academic genomics research hubs
Egypt 12.5% CAGR Population-scale health digitization
Rest of MEA 28.0% of regional share International aid-funded health programs

 

Saudi Arabia's Vision 2030 healthcare transformation and the UAE's status as a regional medical-tourism hub are positioning the Gulf states as the primary growth engines for the Nutrigenomics Market in the MEA region [22].

 

Nutrigenomics Market By Region, 2025-2035

Competitive Benchmarking

The Nutrigenomics Market exhibits medium concentration, with the top five players holding an estimated 35–40% combined revenue share. The HHI index sits in the 800–1,200 range, indicating a moderately fragmented landscape where DTC genetic testing companies compete alongside legacy supplement manufacturers and emerging AI-driven platforms. Strategic differentiation centers on three axes: breadth of genetic panel coverage, quality of personalized recommendation algorithms, and control over downstream supplement fulfillment.

Company Est. Revenue Share Range Key Offerings for Nutrigenomics Market Strategic Positioning
Nutrigenomix Inc. ~7–10% Clinician-grade 70+ gene panel, practitioner network Clinical channel leader, research-validated panels
Prenetics (DNAfit) ~6–9% Consumer genetic kits, CircleDNA platform DTC scale, Asia-Pacific footprint
23andMe ~5–8% Health + ancestry reports, pharmacogenomics add-ons Massive consumer database, brand recognition
Viome Life Sciences ~4–7% mRNA-based gut-health tests, precision supplements Microbiome-first approach, subscription model
Metagenics ~4–6% Practitioner-dispensed supplements, genetic guidance tools Clinical nutrition heritage, B2B channel strength
DSM-Firmenich ~3–5% Personalized nutrition ingredients, B2B formulation platforms Ingredients giant, upstream supply position
Nestlé Health Science ~3–5% Consumer health brands, nutrigenomic R&D partnerships Global distribution, brand trust
BASF Human Nutrition ~2–4% Vitamin and omega-3 ingredient supply, co-development Upstream ingredient positioning
GenoPalate ~2–3% DNA-based food recommendations, consumer app Affordable DTC entry point
Orig3n ~1–3% Fitness and nutrition gene panels, retail kits Mass-market retail distribution

 

 

Recent News & Developments

 

  • Viome Life Sciences (August 2023): Secured USD 86 million in Series C funding to scale its mRNA-based precision supplement line across North America and Asia-Pacific [10].
  • 23andMe (November 2024): Formally expanded its premium digital subscription ecosystems by incorporating advanced, multi-condition polygenic risk scores (PRS) to provide users with proactive, clinical-grade predisposition reports for major hereditary cancers, including detailed tracking for breast, colorectal, and prostate oncological risk states.

 

  • FDA (May 2024): Published its highly anticipated Final Rule governing Laboratory Developed Tests (LDTs), amending regulations to state that in vitro diagnostics manufactured by laboratories are medical devices under the Federal Food, Drug, and Cosmetic Act, establishing a strict four-year phased enforcement roadmap for data validation.
  • Nestlé Health Science (August 2023): Solidified its leading vertical position within full-stack personalized nutrition ecosystems by driving international distribution networks for its vertically integrated Persona platform, utilizing automated data algorithms to compile consumer lifestyle indicators into targeted monthly subscription supplement boxes.

 

 

Nutrigenomics Market Report Scope

Parameter Detail
Market Scope Global Nutrigenomics Market, covering applications, products, end users, distribution channels, and five geographic regions
Study Period 2021–2035
CAGR (2026–2035) 16.4%
Base Year Market Size USD 0.86 Billion (2025)
Forecast Endpoint USD 3.89 Billion (2035)
Fastest Growing Segment Probiotics & Prebiotics (by product); Cancer (by application); Asia-Pacific (by region)
Companies Profiled 10 (Nutrigenomix, Prenetics, 23andMe, Viome, Metagenics, DSM-Firmenich, Nestlé Health Science, BASF, GenoPalate, Orig3n)
Valuation Currency USD Billion

 

 

FAQs

How do reimbursement policies affect the commercial viability of nutrigenomic testing?
Reimbursement remains limited to genetic counseling in most U.S. commercial plans, though Medicare Advantage pilots are testing coverage for metabolic-risk gene panels [2]. Broader payer adoption would significantly lower out-of-pocket costs and accelerate volume growth.
What distinguishes clinical-grade from consumer-grade nutrigenomic panels?
Clinical panels analyze 50–70+ validated gene variants under CLIA-certified lab protocols, while consumer kits typically cover 20–30 markers with lower analytical stringency [14]. Regulatory oversight and report interpretation by licensed practitioners set the clinical tier apart.
How are nutrigenomics companies addressing genetic data portability?
Leading platforms now offer downloadable raw-data files in VCF or CSV format, enabling consumers to transfer results between services [13]. Interoperability standards remain nascent, but the Global Alliance for Genomics and Health is developing data-sharing frameworks.
What role does epigenetics play in next-generation nutrigenomics?
Epigenetic markers — particularly DNA methylation patterns — reveal how lifestyle and diet modify gene expression without altering the underlying sequence [12]. Integrating epigenomic data enables dynamic, time-sensitive dietary recommendations beyond static genotype analysis.
How do subscription models compare with one-time purchase models in profitability?
Subscription platforms achieve 3–4x higher customer lifetime value than one-time kit sellers, driven by recurring supplement revenue and lower churn from personalized engagement loops [8]. Gross margins on subscriptions typically exceed 70%.
What cybersecurity standards apply to stored consumer genetic data?
U.S. providers must comply with HIPAA when handling health-linked genetic data, while EU operators fall under GDPR's special-category data provisions [13]. SOC 2 Type II certification is emerging as the de facto industry benchmark for data-security posture.
How are food manufacturers integrating nutrigenomic insights into product development?
CPG companies use aggregated, anonymized nutrigenomic datasets to identify population-level nutrient gaps and formulate targeted functional foods [12]. This data-driven approach reduces R&D cycle times and improves product-market fit for fortified and functional categories.    
What is the current size of the nutrigenomics market?
The nutrigenomics market reached USD 0.86 billion in 2025 and is projected to reach USD 3.89 billion by 2035.
What is the CAGR of the nutrigenomics market?
The nutrigenomics market is projected to grow at a CAGR of 16.4% during the forecast period 2026–2035.
Which region leads the nutrigenomics market?
North America holds the largest share at 42.0%, while Asia-Pacific is the fastest-growing region at 14.5% CAGR.
What is driving growth in the nutrigenomics market?
Growth in the nutrigenomics market is primarily driven by rapidly falling genome-sequencing costs, a global policy shift toward preventive healthcare, and the integration of AI-powered nutrition algorithms that enable personalized, gene-guided dietary recommendations at scale.
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, genomic research repositories, peer-reviewed nutritional science journals, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Food Safety Authority (EFSA), US Federal Trade Commission (FTC), National Institutes of Health (NIH) National Human Genome Research Institute (NHGRI), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, World Health Organization (WHO) Global Health Observatory, Organisation for Economic Co-operation and Development (OECD) Health Statistics, European Commission Joint Research Centre (JRC), International Society of Nutrigenetics/Nutrigenomics (ISNN), Academy of Nutrition and Dietetics, Human Genome Project archives, and national genomic databases from key markets. These sources were utilized to collect genetic testing volume statistics, regulatory approval data for direct-to-consumer (DTC) genetic tests, clinical validation studies on gene-diet interactions, population genomic prevalence data, obesity and metabolic disorder epidemiology, sequencing cost trends, and personalized nutrition adoption metrics across reagents/kits, genetic testing services, and nutraceutical applications.

 

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources consist of CEOs, Chief Scientific Officers (CSOs), VPs of Genomics, regulatory affairs heads, bioinformatics directors, and commercial leaders from nutrigenomics testing companies, personalized nutrition platforms, genomic assay manufacturers, and functional food developers. Registered dietitian nutritionists (RDNs), clinical genomics specialists, metabolic disorder clinicians, medical directors of corporate wellness programs, procurement officers from hospitals and diagnostic laboratories, and research scientists from academic nutrigenomics centers comprised demand-side sources. Primary research has confirmed the timelines of genetic testing pipelines, validated market segmentation across obesity management, cardiovascular health, and metabolic disorder applications, and gathered insights on the clinical adoption of personalized nutrition protocols, DTC pricing strategies, bioinformatics platform integration, and regulatory compliance for gene-based health claims.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping and genetic testing volume analysis. The methodology included:

Identification of 50+ key manufacturers and service providers across North America, Europe, Asia-Pacific, and Latin America specializing in genetic testing kits, reagents, bioinformatics platforms, and personalized nutrition services

Product mapping across gene panels for macronutrient metabolism, micronutrient absorption, food intolerance, obesity risk, cardiovascular markers, and sports performance categories

Analysis of reported and modeled annual revenues specific to nutrigenomics portfolios, including DTC testing subscriptions and clinical diagnostic services

Coverage of manufacturers and service providers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (genetic test volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across testing kits, nutritional supplements, and digital health platforms

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.